Jakafi (ruxolitinib) — Highmark
Polycythemia vera
Initial criteria
- age ≥ 18 years
- diagnosis of polycythemia vera
- therapeutic failure, contraindication, or intolerance to hydroxyurea
Reauthorization criteria
- prescriber attests member has experienced a reduction in spleen size OR improvement in symptoms